Hasanzadeh Malihe, Rejali Marzieh, Khalili-Tanha Ghazaleh, Mehramiz Mehraneh, Yavari Negar, Nazari Elham, Malakuti Parnian, Maleki Faezeh, Ghorbannezhad Ghazaleh, Rafiei Mahdi, Mirani Anahita, Gholampoor-Shamkani Negar, Saber Hoda, Mousavi-Seresht Leila, Emamdadi-Aliabad Zohreh, Mahdian Zahra, Akbari Mahdieh, Ferns Gordon A, Al Moustafa Ala-Eddin, Avan Amir
Department of Gynecology Oncology, Woman Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Infect Disord Drug Targets. 2025;25(4):e18715265307980. doi: 10.2174/0118715265307980240826060516.
Cervical cancer is among the most common types of cancer in women and is associated with human papillomavirus (HPV) infection. The association between cervical cancer and high-risk HPV infection has been well documented. However, the effect of simultaneous infection with high- and low-risk HPV or low-risk HPV alone on the risk of developing cervical malignancy remains unanswered in guidelines.
We investigated the association of high and low-risk HPVs (HR or LR) genotypes with cervical carcinoma risk and pathological and cytological information in cases recruited from a population- based cohort study of 790 patients. Correlation matrix and t-test were used for analysis.
The percentage of HR+LR and HR-HPV16/18 were 9.30% and 11.20% in class II, 7.15% and 7.10% in class IV, and 7.15% and 5.80% in As-CUS smears. Interestingly, concurrent infection with HR-HPV and LR-HPV types led to a significant reduction in the risk of developing malignancy compared to the high-risk group (OR=0.3 (0.098-0.925), pvalue= 0.04). The percentage of individuals with cervical malignancy was 10.2% and 28.2% within the co-infected and the HR-HPV participants.
Our findings suggest that simultaneous infection with high- and low-risk HPV may reduce the risk of cervical malignancy.
宫颈癌是女性最常见的癌症类型之一，与人乳头瘤病毒（HPV）感染有关。宫颈癌与高危HPV感染之间的关联已有充分记录。然而，同时感染高危和低危HPV或仅感染低危HPV对发生宫颈恶性肿瘤风险的影响在指南中仍未得到解答。
我们在一项基于人群的队列研究中招募了790例患者，调查了高危和低危HPV（HR或LR）基因型与宫颈癌风险以及病理和细胞学信息之间的关联。采用相关矩阵和t检验进行分析。
II级涂片样本中HR+LR和HR-HPV16/18的比例分别为9.30%和11.20%，IV级涂片样本中分别为7.15%和7.10%，意义不明确的不典型鳞状细胞（As-CUS）涂片样本中分别为7.15%和5.80%。有趣的是，与高危组相比，同时感染HR-HPV和LR-HPV类型导致发生恶性肿瘤的风险显著降低（比值比=0.3（0.098-0.925），p值=0.04）。在合并感染组和HR-HPV参与者中，宫颈恶性肿瘤患者的比例分别为10.2%和28.2%。
我们的研究结果表明，同时感染高危和低危HPV可能会降低宫颈恶性肿瘤的风险。
